American Journal of Transplantation最新文献_第2页

Metabolic changes during cold ischemic preservation and reperfusion in porcine lung transplants. 猪肺移植冷缺血保存和再灌注过程中的代谢变化。

IF 8.8 2区医学

American Journal of Transplantation Pub Date : 2025-05-17 DOI: 10.1016/j.ajt.2025.05.021

Lubiao Liang,Michael K Hsin,Yajin Zhao,Aizhou Wang,Tiago Machuca,Jonathan Yeung,Marcelo Cypel,Shaf Keshavjee,Mingyao Liu

{"title":"Metabolic changes during cold ischemic preservation and reperfusion in porcine lung transplants.","authors":"Lubiao Liang,Michael K Hsin,Yajin Zhao,Aizhou Wang,Tiago Machuca,Jonathan Yeung,Marcelo Cypel,Shaf Keshavjee,Mingyao Liu","doi":"10.1016/j.ajt.2025.05.021","DOIUrl":"https://doi.org/10.1016/j.ajt.2025.05.021","url":null,"abstract":"Lung transplantation is a cornerstone in treating patients with end-stage lung disease, yet ischemia-reperfusion injury (IRI) poses significant complications in post-transplant recovery. This study aimed to understand the effects of donor type, cold ischemic time (CIT) and the reperfusion on metabolic changes in lung grafts. Porcine donor lungs underwent different CIT on ice: minimal time (control), 6 hours (CIT-6H), and 30 hours (CIT-30H). Additionally, lungs from brain death (BD) animals underwent 24-hour CIT (BD-CIT-24H). Both CIT-30H and BD-CIT-24H lungs underwent ex vivo lung perfusion for 12 hours, followed by left lung transplantation and reperfusion for 2 hours. Lung tissue samples were subjected to metabolomic analysis. Cold preservation induced time-dependent changes of certain metabolites. In BD-CIT-24H group, while most trends in metabolite levels were similar to the CIT-30H group, certain metabolite levels were markedly different. In CIT-30H lungs, reperfusion induced significant changes in the carbohydrate and amino acid pathways, along with consumption of energy substrates and reduction in antioxidants. BD donor lungs exhibited significantly reduction in lysophospholipids after reperfusion. Understanding these metabolic changes in the lung grafts shed lights on the mechanism of IRI, offering valuable insights for future development of targeted strategies to improve donor lung preservation and clinical outcome.","PeriodicalId":123,"journal":{"name":"American Journal of Transplantation","volume":"34 1","pages":""},"PeriodicalIF":8.8,"publicationDate":"2025-05-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144097700","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Waitlist outcomes after acuity circle-based distribution in pediatric liver transplantation. 在儿童肝移植中基于视度圈分布的等待列表结果。

IF 8.8 2区医学

American Journal of Transplantation Pub Date : 2025-05-17 DOI: 10.1016/j.ajt.2025.05.019

Denise J Lo,Joseph F Magliocca,Katherine Ross-Driscoll

{"title":"Waitlist outcomes after acuity circle-based distribution in pediatric liver transplantation.","authors":"Denise J Lo,Joseph F Magliocca,Katherine Ross-Driscoll","doi":"10.1016/j.ajt.2025.05.019","DOIUrl":"https://doi.org/10.1016/j.ajt.2025.05.019","url":null,"abstract":"Pediatric liver transplant (LT) waitlist mortality remains unacceptably high. In 2020, the Organ Procurement and Transplantation Network (OPTN) implemented acuity circle (AC)-based liver distribution and national pediatric prioritization for pediatric donor livers. Using OPTN data, waitlist outcomes for pediatric LT candidates listed between February 4, 2016 and February 3, 2024, were studied by age group and era relative to AC implementation. There were 5,605 waitlist registrations and 3,778 liver transplants. At 1 year, cumulative incidence of transplant was 77.8% pre-AC vs 79.9% post-AC; cumulative incidence of mortality was 5.4% pre-AC vs 5.9% post-AC. Median allocation Model for End-Stage Liver Disease/Pediatric Model for End-Stage Liver Disease score at LT significantly decreased across all age groups post-AC (p<0.001). Candidates age 12-17 years experienced higher cumulative incidence of transplant (65.6% pre-AC vs 79.5% post-AC at 1 year), decreased median time to transplant (66 days pre-AC vs 37 days post-AC, p<0.001), and increased proportion of pediatric donor livers (37.9% pre-AC vs 66.2% post-AC, p<0.001). AC group was associated with increased likelihood of transplant for those age 12-17 years and increased likelihood of waitlist mortality for those age 1-5 years. LT candidates age 12-17 years derived the most benefit from AC-based liver distribution.","PeriodicalId":123,"journal":{"name":"American Journal of Transplantation","volume":"135 1","pages":""},"PeriodicalIF":8.8,"publicationDate":"2025-05-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144097701","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Soluble CD95L is a prognostic marker in Central Nervous System Post-Transplant Lymphoproliferative Disorders. 可溶性CD95L是中枢神经系统移植后淋巴增生性疾病的预后标志物。

IF 8.8 2区医学

American Journal of Transplantation Pub Date : 2025-05-13 DOI: 10.1016/j.ajt.2025.05.010

Antoine Tichadou,Eden Lebrault,Assia Samri,Marine Baron,Cécilia Nakid-Cordero,David Lavergne,Véronique Morin,Oulfata Mze,Noureddine Balegroune,Xiaozhen Liang,Sylvain Choquet,Amélie Guihot,Patrick Legembre,Murielle Roussel,

{"title":"Soluble CD95L is a prognostic marker in Central Nervous System Post-Transplant Lymphoproliferative Disorders.","authors":"Antoine Tichadou,Eden Lebrault,Assia Samri,Marine Baron,Cécilia Nakid-Cordero,David Lavergne,Véronique Morin,Oulfata Mze,Noureddine Balegroune,Xiaozhen Liang,Sylvain Choquet,Amélie Guihot,Patrick Legembre,Murielle Roussel,","doi":"10.1016/j.ajt.2025.05.010","DOIUrl":"https://doi.org/10.1016/j.ajt.2025.05.010","url":null,"abstract":"CD95L is a transmembrane cytokine mainly expressed by activated T and NK cells to contract the immune response through cell-cell contact. Conversely, after cleavage by metalloproteases, this ligand releases a soluble CD95L (sCD95L) that stimulates the immune response and its antitumor activity. In Post-Transplant Lymphoproliferative Disorders (PTLDs), we hypothesized that the concentration of sCD95L could exert a biological function and affect clinical outcomes by modulating the immune response. Using the K-VIROGREF biobank, we quantified sCD95L in 163 patients with PTLD, 16 transplant controls and 28 healthy donors. Transplant recipients had higher plasma levels of sCD95L than healthy donors. More interestingly, patients with PTLD and high concentration of sCD95L had better clinical outcomes than patients with lower concentration, particularly those with central nervous system (CNS) involvement known to have poor survivals. At the cellular level, only NK and NKT-like cells fractions were reduced in the blood of patients with CNS-PTLD and high concentration of sCD95L, suggesting that sCD95L may either promote the trafficking of these cells within tumors or modulate their differentiation/survival. In conclusion, we showed in this exploratory analysis that plasma concentration of sCD95L might be a prognostic marker in patients with PTLD, particularly in those with CNS involvement.","PeriodicalId":123,"journal":{"name":"American Journal of Transplantation","volume":"1 1","pages":""},"PeriodicalIF":8.8,"publicationDate":"2025-05-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144065585","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Continued Optimism for the use of Imlifidase for Desensitization in Kidney Transplant. 对在肾移植中使用Imlifidase脱敏继续持乐观态度。

IF 8.8 2区医学

American Journal of Transplantation Pub Date : 2025-05-13 DOI: 10.1016/j.ajt.2025.05.015

Carrie A Schinstock,Mark Stegall

引用次数: 0

Measles update-United States, January 1-April 17, 2025. 麻疹更新-美国，2025年1月1日至4月17日。

IF 8.9 2区医学

American Journal of Transplantation Pub Date : 2025-05-13 DOI: 10.1016/j.ajt.2025.05.014

Marcus R Pereira

引用次数: 0

Unraveling CD8+ T Cell Alloimmunity: Insights into the Direct Pathway of Antigen Recognition from Modern Experimental Tools. 揭示CD8+ T细胞同种免疫：从现代实验工具了解抗原识别的直接途径。

IF 8.8 2区医学

American Journal of Transplantation Pub Date : 2025-05-13 DOI: 10.1016/j.ajt.2025.05.009

Joel S Freibaum,Riley P Leathem,William Braaton,Scott M Krummey

{"title":"Unraveling CD8+ T Cell Alloimmunity: Insights into the Direct Pathway of Antigen Recognition from Modern Experimental Tools.","authors":"Joel S Freibaum,Riley P Leathem,William Braaton,Scott M Krummey","doi":"10.1016/j.ajt.2025.05.009","DOIUrl":"https://doi.org/10.1016/j.ajt.2025.05.009","url":null,"abstract":"Early experimental investigations of alloimmunity demonstrated that the T cell response against allogeneic antigens is robust and results from a high precursor frequency of responding clones. Seminal studies using cell culture-based methods led to an overall model in which CD8+ T cells are able to recognize self-peptide complexed to allogeneic peptide MHC, termed the direct allogeneic antigen recognition pathway. Recently, three groups used modern experimental approaches, including MHC class I tetramers, to further investigate the nature of direct allogeneic antigen recognition by CD8+ T cells in mice and humans. In a model of liver-induced transplant tolerance, Son et al showed that the MHC class I alloimmune CD8+ T cell response is peptide dependent. Cohen et al elucidated the H-Ld QL9 allogeneic epitope and showed that reactive CD8+ T cells were peptide discriminating. Zhang et al engineered artificial antigen presenting cells to show that human alloreactive CD8+ T cells against HLA-A antigens were MHC restricted, and demonstrated a public HLA-A2 CD8+ T cell response in four donors. Through new experimental tools, these studies offer granular evidence of the mechanisms by which CD8+ T cells recognize allogeneic antigen, and provide a framework for future approaches to selectively target them.","PeriodicalId":123,"journal":{"name":"American Journal of Transplantation","volume":"28 1","pages":""},"PeriodicalIF":8.8,"publicationDate":"2025-05-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144065586","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Recommendations to Overcome Barriers to Transplant Fellowship Training: A Report from the American Society of Transplantation Fellows Task Force. 克服移植研究员培训障碍的建议：一份来自美国移植研究员协会工作组的报告。

IF 8.8 2区医学

American Journal of Transplantation Pub Date : 2025-05-13 DOI: 10.1016/j.ajt.2025.05.007

Jon Kobashigawa,Josh Levitsky,Neeraj Singh,Kiran Khush,Sean Pinney,Elizabeth Aby,Aasim Afzal,Deborah Adey,Anshul Bhalla,Mona Doshi,Samira Farouk,Alyson Fox,Shelley Hall,Michelle Kittleson,Lindsay King,Alexander Kuo,Deborah Levine,Yosef Manla,Jamak Modaresi,Arjmand Mufti,Prince Mohan Anand,Michael Nurok,Jp Norvell,Neehar Parikh,Anjana Pillai,Faruq Pradhan,Allison Ramsey,Milagros Samaniego-Picota,Ishna Poojary-Hohman,Manpreet Samra,Deirdre Sawinski,Kelly Schlendorf,Stuart Sweet,Bekir Tanriover,Sarthak Virmani,Roy D Bloom

{"title":"Recommendations to Overcome Barriers to Transplant Fellowship Training: A Report from the American Society of Transplantation Fellows Task Force.","authors":"Jon Kobashigawa,Josh Levitsky,Neeraj Singh,Kiran Khush,Sean Pinney,Elizabeth Aby,Aasim Afzal,Deborah Adey,Anshul Bhalla,Mona Doshi,Samira Farouk,Alyson Fox,Shelley Hall,Michelle Kittleson,Lindsay King,Alexander Kuo,Deborah Levine,Yosef Manla,Jamak Modaresi,Arjmand Mufti,Prince Mohan Anand,Michael Nurok,Jp Norvell,Neehar Parikh,Anjana Pillai,Faruq Pradhan,Allison Ramsey,Milagros Samaniego-Picota,Ishna Poojary-Hohman,Manpreet Samra,Deirdre Sawinski,Kelly Schlendorf,Stuart Sweet,Bekir Tanriover,Sarthak Virmani,Roy D Bloom","doi":"10.1016/j.ajt.2025.05.007","DOIUrl":"https://doi.org/10.1016/j.ajt.2025.05.007","url":null,"abstract":"With the expansion of solid organ transplantation activities in the US, there is a critical need for more transplant care providers and trainees to sustain and advance the field of transplantation. However, there has been a pending shortage of trainees pursuing transplant fellowship training in the U.S. in recent years. To address this issue, the American Society of Transplantation (AST) organized the Fellows' Task Force, including representatives of all four major organs from various AST communities of practice, to understand the drivers of this pending shortage and develop strategies to increase interest in transplant specialization. The task force identified four areas of focus, including early & sustained exposure to transplant medicine, awareness through education, flexible fellowships & pathways to transplant, and work/life resources. Based on these focus areas, the task force developed recommendations and action items, which were compiled into a report to be implemented by individuals, institutions, communities of practice (work groups), and societies such as the AST. We hope that this report will be the first step in overcoming barriers and concerns to encourage the pursuit of specialization in transplantation in the US.","PeriodicalId":123,"journal":{"name":"American Journal of Transplantation","volume":"15 1","pages":""},"PeriodicalIF":8.8,"publicationDate":"2025-05-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144065874","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Acetylcholine from B lymphocytes orchestrates liver regeneration. 来自B淋巴细胞的乙酰胆碱协调肝脏再生。

IF 8.8 2区医学

American Journal of Transplantation Pub Date : 2025-05-12 DOI: 10.1016/j.ajt.2025.05.012

Christopher Bricogne,Fadi Issa

引用次数: 0

Donor-specific Mesenchymal Stem Cell Infusion in Human and Non-human Primate Kidney Transplantation. 供体特异性间充质干细胞输注在人和非人灵长类动物肾移植中的应用。

IF 8.8 2区医学

American Journal of Transplantation Pub Date : 2025-05-12 DOI: 10.1016/j.ajt.2025.05.008

Imran J Anwar,Shu Li,Michael Mulvihill,Robin Schmitz,Brian Shaw,Qimeng Gao,Sherri Swan-Nesbit,Lynn A Cheatham,Tam How,Allison Miller,Kyha Williams,Fang-Fang Yin,William Giles,Joanne Kurtzberg,Sindhu Chandran,Nancy Bridges,Lyudmila Lyakh,Cynthia Breeden,Krupa Gandhi,Michelle Sever,Mingqing Song,He Xu,Allan D Kirk

{"title":"Donor-specific Mesenchymal Stem Cell Infusion in Human and Non-human Primate Kidney Transplantation.","authors":"Imran J Anwar,Shu Li,Michael Mulvihill,Robin Schmitz,Brian Shaw,Qimeng Gao,Sherri Swan-Nesbit,Lynn A Cheatham,Tam How,Allison Miller,Kyha Williams,Fang-Fang Yin,William Giles,Joanne Kurtzberg,Sindhu Chandran,Nancy Bridges,Lyudmila Lyakh,Cynthia Breeden,Krupa Gandhi,Michelle Sever,Mingqing Song,He Xu,Allan D Kirk","doi":"10.1016/j.ajt.2025.05.008","DOIUrl":"https://doi.org/10.1016/j.ajt.2025.05.008","url":null,"abstract":"We report the results of two independent, concurrently performed studies evaluating the safety and efficacy of donor-derived mesenchymal stromal cell (MSC) infusions in inducing immune-tolerance in nonhuman primate (NHP) and human kidney transplant recipients treated with depletional induction and belatacept/sirolimus maintenance. Fifteen NHPs received rhesus ATG induction and were divided in three groups: control (n=6), pre-transplant thymic irradiation (TI, n=4), and TI with monthly donor-MSC infusion (n=5). Sirolimus was discontinued at day-180, and belatacept at day-365 post-transplantation. In humans, six patients enrolled in ITN062ST underwent transplantation with alemtuzumab induction; four received 12 monthly donor-MSC infusions followed by immunosuppression withdrawal (ISW) if eligible. Donor-MSC infusion was acutely well-tolerated in humans and NHPs. Chimerism was not established, and tolerance was not induced in either study. Two of five NHPs that received MSCs rejected while on belatacept monotherapy with detectable donor-specific antibody (DSA). Two patients did not initiate ISW due to de novo DSA and borderline rejection, and two patients failed ISW due to reversible rejection. In conclusion, donor-MSCs can be given to NHPs or humans repeatedly without acute consequences, but they neither lead to detectable chimerism nor induce tolerance. In a subset of recipients, infused MSCs can be sensitizing. Trial Registration. ClinicalTrials.gov - NCT03504241.","PeriodicalId":123,"journal":{"name":"American Journal of Transplantation","volume":"29 1","pages":""},"PeriodicalIF":8.8,"publicationDate":"2025-05-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143982455","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Beyond the HOPE Act: Roadmap to Expanding Kidney and Liver Transplants for People with Human Immunodeficiency Virus Utilizing Grafts from Donors with Human Immunodeficiency Virus. 超越希望法案：利用人类免疫缺陷病毒供体移植扩大人类免疫缺陷病毒患者肾脏和肝脏移植的路线图。

IF 8.8 2区医学

American Journal of Transplantation Pub Date : 2025-05-12 DOI: 10.1016/j.ajt.2025.05.013

Tzu-Hao Lee,Kara Wegermann,Ken Sutha,George Cholankeril,Chia-Yu Chu,Nhu Thao Nguyen Galvan,Abbas Rana,John A Goss,Tyler Lambing,Felice Cinque,Giada Sebastiani,Keyur Patel,Susanna Naggie,Cameron R Wolfe

{"title":"Beyond the HOPE Act: Roadmap to Expanding Kidney and Liver Transplants for People with Human Immunodeficiency Virus Utilizing Grafts from Donors with Human Immunodeficiency Virus.","authors":"Tzu-Hao Lee,Kara Wegermann,Ken Sutha,George Cholankeril,Chia-Yu Chu,Nhu Thao Nguyen Galvan,Abbas Rana,John A Goss,Tyler Lambing,Felice Cinque,Giada Sebastiani,Keyur Patel,Susanna Naggie,Cameron R Wolfe","doi":"10.1016/j.ajt.2025.05.013","DOIUrl":"https://doi.org/10.1016/j.ajt.2025.05.013","url":null,"abstract":"People living with HIV (PWH) face limited access to organ transplantation despite higher rates of end-organ disease. The HIV Organ Policy Equity (HOPE) Act, enacted in 2015, allowed transplants from donors with HIV to recipients with HIV (HIV D+/R+) under research protocols. Studies have since demonstrated overall comparable outcomes between HIV D+/R+ and HIV D-/R+ transplants, leading to the removal of the research requirement for HIV D+/R+ kidney and liver transplants in November 2024. However, some remaining medical concerns and systemic barriers still need to be addressed, especially for centers that did not participate in the HOPE Act. This manuscript reviews the history, evidence, and key considerations for HIV D+/R+ kidney and liver transplants. Furthermore, a roadmap for implementation, emphasizing the need for reviewing local regulations, establishing multidisciplinary teams, developing personalized protocols, providing medical and culture training, engaging organ procurement organizations and local PWH community, and continuing data collection and quality improvement, is discussed. The removal of research restrictions offers a critical opportunity to reduce disparities in transplant access for PWH. Transplant providers should embrace this opportunity to expand access while continuing to address the remaining medical and systemic challenges to ensure that more PWH receive life-saving transplants.","PeriodicalId":123,"journal":{"name":"American Journal of Transplantation","volume":"5 1","pages":""},"PeriodicalIF":8.8,"publicationDate":"2025-05-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143982456","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0